Metabolism of NNK Among African Americans

NCT ID: NCT01158456

Last Updated: 2023-04-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

161 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-12-31

Study Completion Date

2017-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Metabolism and DNA adduct formation are critical in cancer induction by NNK. The investigators goal is to understand whether the observed ethnic/racial differences in lung cancer incidence are due to variations in NNK metabolism. The investigators overall hypothesis is that cancer susceptibility relates to carcinogen dose and to the balance between carcinogen metabolic activation and detoxification. The investigators propose to test this hypothesis via investigation of potential differences in NNK metabolic activation and detoxification in African American and European American smokers.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Lung cancer is the most common cause of cancer death in the United States, with the annual number of cases estimated at 162,460 deaths per year. It is more prevalent in African Americans as compared to European Americans. Cigarette smoking causes up to 90% of lung cancer, being the major risk factor in both African Americans and European Americans.

Tobacco-specific nitrosamines (TSNA) are among the most significant carcinogens in tobacco products. Multiple international studies clearly document the occurrence of substantial amounts of these carcinogens in both unburned tobacco and tobacco smoke. One of the most prevalent of these compounds, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), is present in both unburned tobacco and cigarette smoke, and is a remarkably effective lung carcinogen in laboratory animals, inducing lung tumors in rodents independent of the route of administration. 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), a metabolite of NNK, is also a pulmonary carcinogen. NNK has been classified by the International Agency for Research on Cancer as a Group 1 carcinogen (carcinogenic to humans). Consistent with this, 2 recent studies by our group have demonstrated that levels of NNAL in serum or urine are related to lung cancer in smokers.

Our primary aim is to conduct a comprehensive analysis of urinary biomarkers of NNK metabolic activation and detoxification in African American and European American smokers. We hypothesize that, after adjustment for smoking level, the relative contribution of the biomarkers of NNK metabolic activation to the total amount of NNK metabolites will be higher in African Americans as compared to European Americans. Our secondary aim is to measure in exfoliated oral mucosa cells of African American and European American smokers DNA adducts formed as a result of NNK metabolic activation. The results of these measurements will offer a direct measure of NNK-induced DNA damage in smokers, and will be critical to an understanding of the balance between the urinary excretion of NNK metabolites and the extent of NNK DNA binding. We hypothesize that African Americans will have in the DNA of their oral mucosa cells higher levels of NNK-derived DNA adducts as compared to European Americans. Finally, we will investigate the relationship between levels of NNK-derived DNA adducts measured in oral mucosa cells and the rates of repair of these adducts in cultured lymphocytes from our subjects. These measurements will allow us to evaluate more fully the role of variations in NNK metabolism in the observed differences in lung cancer risk between European American and African American smokers. We expect that that African Americans will have lower capacity to repair NNK-induced DNA damage as compared to European Americans, and this will correlate with higher levels of NNK-derived buccal DNA adducts.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

African Americans

Subjects will be classified as African American if they report themselves, biological parents and both sets of biological grandparents as African American or African descent.

No interventions assigned to this group

European American

Subjects will be classified as European American if they report themselves, biological parents and both sets of biological grandparents as European American or European descent.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female subjects with a smoking history of at least 10 cigarettes daily for at least 1 year;
2. Subjects report themselves, biological parents and both sets of biological grandparents as

* African American or African descent or
* European American or European descent
3. Subjects are in apparently good physical health (no unstable medical condition)
4. Subjects are in stable, good mental health (e.g. not currently, within the past 6 months, experiencing unstable or untreated psychiatric diagnosis, including substance abuse, as determined by the PRIME-MD);
5. Subjects have provided written informed consent to participate in the study.

Exclusion Criteria

1. Unstable medical conditions including cancer, coronary heart disease and arrhythmia
2. Cannot or unwilling to identify ethnic/racial ancestry
3. Women who are currently pregnant or breast feeding
4. Currently using any other tobacco or nicotine-containing product
5. Currently taking any medications that affect relevant metabolic enzymes.
Minimum Eligible Age

21 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Cancer Institute (NCI)

NIH

Sponsor Role collaborator

Masonic Cancer Center, University of Minnesota

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dorothy K Hatsukami, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

University of Minnesota

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tobacco Research Programs University of Minnesota

Minneapolis, Minnesota, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1P01CA138338-01A1

Identifier Type: NIH

Identifier Source: secondary_id

View Link

2010NTLS056

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Genetic Susceptibility to Bladder Cancer
NCT00848289 ACTIVE_NOT_RECRUITING